XyloCor's XC001 Gene Therapy and the Quest for a New Era in Refractory Angina Treatment

XyloCor Therapeutics, a forward-thinking company in the biotechnology sector, is at the forefront of developing a promising new approach: a gene therapy candidate named XC001 (encoberminogene rezmadenovec)